Less than a year ago, Pfizer Inc. was securing reimbursement in the UK for its sickle cell disease (SCD) drug, Oxbryta (voxelitor), while hematologists were debating how the increasing number of options for SCD – including Oxbryta – would fit into the treatment paradigm. Now, the URL for the drug’s website redirects to Pfizer’s announcement that it is pulling the drug from the market, while European regulators are recommending suspension of its marketing authorization there.
The New York-based drug maker said 25 September after the stock market closed that it was voluntarily withdrawing all lots...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?